171 related articles for article (PubMed ID: 38504247)
1. Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients.
Nili M; Epstein AJ; Nunag D; Olson A; Borah BJ
BMC Pulm Med; 2024 Mar; 24(1):141. PubMed ID: 38504247
[TBL] [Abstract][Full Text] [Related]
2. Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients.
Nili M; Epstein AJ; Nunag D; Olson A; Borah B
BMC Pulm Med; 2023 Jun; 23(1):230. PubMed ID: 37370093
[TBL] [Abstract][Full Text] [Related]
3. Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis.
Corral M; Chang E; Broder MS; Gokhale S; Reddy SR
J Comp Eff Res; 2020 Sep; 9(13):933-943. PubMed ID: 32851849
[No Abstract] [Full Text] [Related]
4. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Corral M; DeYoung K; Kong AM
BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
[TBL] [Abstract][Full Text] [Related]
5. Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis.
Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; de Andrade J
J Med Econ; 2022; 25(1):532-540. PubMed ID: 35321616
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
[TBL] [Abstract][Full Text] [Related]
7. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis.
Mooney J; Reddy SR; Chang E; Broder MS; Gokhale S; Corral M
J Manag Care Spec Pharm; 2021 Dec; 27(12):1724-1733. PubMed ID: 34818092
[No Abstract] [Full Text] [Related]
8. Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis.
Dempsey TM; Payne S; Sangaralingham L; Yao X; Shah ND; Limper AH
Ann Am Thorac Soc; 2021 Jul; 18(7):1121-1128. PubMed ID: 33465323
[No Abstract] [Full Text] [Related]
9. Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
Cottin V; Spagnolo P; Bonniaud P; Dalon F; Nolin M; Kirchgässler KU; Van Ganse E; Belhassen M
Respir Med Res; 2023 Jun; 83():100951. PubMed ID: 36434913
[TBL] [Abstract][Full Text] [Related]
10. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
Belhassen M; Dalon F; Nolin M; Van Ganse E
Respir Res; 2021 May; 22(1):135. PubMed ID: 33947414
[TBL] [Abstract][Full Text] [Related]
11. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.
Huang TH; Kuo CW; Chen CW; Tseng YL; Wu CL; Lin SH
BMC Pulm Med; 2021 May; 21(1):165. PubMed ID: 33992083
[TBL] [Abstract][Full Text] [Related]
12. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
13. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
Bonella F; Kreuter M; Hagmeyer L; Neurohr C; Keller C; Kohlhaeufl MJ; Müller-Quernheim J; Milger K; Prasse A;
Respiration; 2016; 92(2):98-106. PubMed ID: 27544537
[TBL] [Abstract][Full Text] [Related]
14. Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older.
Collard HR; Chen SY; Yeh WS; Li Q; Lee YC; Wang A; Raghu G
Ann Am Thorac Soc; 2015 Jul; 12(7):981-7. PubMed ID: 25923447
[TBL] [Abstract][Full Text] [Related]
15. Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy.
Tahara M; Oda K; Yamasaki K; Kawaguchi T; Sennari K; Noguchi S; Sakamoto N; Kawanami T; Mukae H; Yatera K
BMC Pulm Med; 2019 Aug; 19(1):157. PubMed ID: 31438928
[TBL] [Abstract][Full Text] [Related]
16. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population.
Simoni-Wastila L; Wei YJ; Qian J; Zuckerman IH; Stuart B; Shaffer T; Dalal AA; Bryant-Comstock L
Am J Geriatr Pharmacother; 2012 Jun; 10(3):201-10. PubMed ID: 22521808
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting.
Kato M; Sasaki S; Tateyama M; Arai Y; Motomura H; Sumiyoshi I; Ochi Y; Watanabe J; Ihara H; Togo S; Takahashi K
Drug Des Devel Ther; 2021; 15():223-230. PubMed ID: 33500614
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.
Senoo S; Miyahara N; Taniguchi A; Oda N; Itano J; Higo H; Hara N; Watanabe H; Kano H; Suwaki T; Fuchimoto Y; Kajimoto K; Ichikawa H; Kudo K; Shibayama T; Tanimoto Y; Kuyama S; Kanehiro A; Maeda Y; Kiura K;
PLoS One; 2020; 15(8):e0236935. PubMed ID: 32853277
[TBL] [Abstract][Full Text] [Related]
19. Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Brunnemer E; Wälscher J; Tenenbaum S; Hausmanns J; Schulze K; Seiter M; Heussel CP; Warth A; Herth FJF; Kreuter M
Respiration; 2018; 95(5):301-309. PubMed ID: 29490307
[TBL] [Abstract][Full Text] [Related]
20. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
